share_log

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

Virpax製藥 | 8-K：VIRPAX PHARMICALS公佈2024年第二季度業績和近期進展
美股SEC公告 ·  08/13 07:37
Moomoo AI 已提取核心訊息
Virpax Pharmaceuticals, Inc., a Delaware-based company specializing in non-addictive pain management and other pharmaceuticals, reported its financial results for the second quarter ended June 30, 2024, on August 13, 2024. The company announced a decrease in general and administrative expenses to $1.5 million from $1.9 million in the same period the previous year, attributed to reduced severance and insurance expenses. Research and development expenses increased to $2.0 million, up from $1.3 million, mainly due to preclinical activities for their lead asset, Probudur. The operating loss for the quarter was $3.5 million, compared to $3.1 million in 2023. As of June 30, 2024, Virpax had cash reserves of approximately $1.9 million. The company also highlighted recent developments, including positive results from a pharmacokinetics and safety study for Probudur, securing $2.8 million from warrant exercises, and regaining compliance with Nasdaq's minimum bid price requirement. Additionally, Virpax completed a $2.5 million secured loan financing, which led to a reorganization of the company's Board of Directors and the repayment of litigation settlement liabilities.
Virpax Pharmaceuticals, Inc., a Delaware-based company specializing in non-addictive pain management and other pharmaceuticals, reported its financial results for the second quarter ended June 30, 2024, on August 13, 2024. The company announced a decrease in general and administrative expenses to $1.5 million from $1.9 million in the same period the previous year, attributed to reduced severance and insurance expenses. Research and development expenses increased to $2.0 million, up from $1.3 million, mainly due to preclinical activities for their lead asset, Probudur. The operating loss for the quarter was $3.5 million, compared to $3.1 million in 2023. As of June 30, 2024, Virpax had cash reserves of approximately $1.9 million. The company also highlighted recent developments, including positive results from a pharmacokinetics and safety study for Probudur, securing $2.8 million from warrant exercises, and regaining compliance with Nasdaq's minimum bid price requirement. Additionally, Virpax completed a $2.5 million secured loan financing, which led to a reorganization of the company's Board of Directors and the repayment of litigation settlement liabilities.
總部位於特拉華州的Virpax Pharmaceuticals，Inc.專注於非成癮性疼痛管理和其他藥品，在2024年6月30日結束的第二季度業績中宣佈了其財務業績。 公司宣佈將總務和行政費用從上年同期的 $1.9百萬降至 $1.5百萬，歸因於減少的離職和保險費用。研發費用增加到了 $2百萬，比去年同期的 $1.3百萬增加，主要是由於其主要資產Probudur的臨床前研究活動。本季度營業虧損爲 $3.5百萬，而 2023 年的爲 $3.1百萬。 截至 2024年6月30日，Virpax擁有大約 $1.9百萬美金的現金儲備。公司還突出了最新發展，包括Probudur 的藥代動力學和安全性研究的積極結果，從認股權行使中獲得 $2.8百萬的籌資，以及重新符合納斯達克的最低買盤價格要求。此外，Virpax 完成了一筆 $2.5百萬的擔保貸款融資，導致公司董事會的重組和訴訟結算責任的償還。
總部位於特拉華州的Virpax Pharmaceuticals，Inc.專注於非成癮性疼痛管理和其他藥品，在2024年6月30日結束的第二季度業績中宣佈了其財務業績。 公司宣佈將總務和行政費用從上年同期的 $1.9百萬降至 $1.5百萬，歸因於減少的離職和保險費用。研發費用增加到了 $2百萬，比去年同期的 $1.3百萬增加，主要是由於其主要資產Probudur的臨床前研究活動。本季度營業虧損爲 $3.5百萬，而 2023 年的爲 $3.1百萬。 截至 2024年6月30日，Virpax擁有大約 $1.9百萬美金的現金儲備。公司還突出了最新發展，包括Probudur 的藥代動力學和安全性研究的積極結果，從認股權行使中獲得 $2.8百萬的籌資，以及重新符合納斯達克的最低買盤價格要求。此外，Virpax 完成了一筆 $2.5百萬的擔保貸款融資，導致公司董事會的重組和訴訟結算責任的償還。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息